DVA Stock Recent News

DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The rising dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DVA, EHC, OPCH and ADUS are well-poised to gain.

DaVita beat revenue and earnings estimates for its fourth quarter. The company has proven resilient in the wake of the COVID-19 pandemic.

Dialysis provider DaVita reported fourth-quarter financials above Wall Street's consensus.

DaVita's (DVA) robust segmental revenues drive its fourth-quarter performance.

DaVita Inc. (DVA) Q4 2023 Earnings Call Transcript

DaVita HealthCare (DVA) came out with quarterly earnings of $1.87 per share, beating the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.11 per share a year ago.

DaVita forecast 2024 profit above Wall Street estimates on Tuesday on anticipated strong demand for its kidney dialysis services, sending its shares up 4.8% after the bell.

Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.